DOCSLIB.ORG

September, 2019 Chief Research Officer Associate Dean of Clinical

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
September, 2019 Chief Research Officer Associate Dean of Clinical Chief Research Officer Dartmouth-Hitchcock Associate Dean of Clinical Research Geisel School of Medicine at Dartmouth Leadership Profile: September, 2019 Table of Contents The Opportunity 3 Full Position Description 4-5 About the Office of Research Operations 6 About SYNERGY �������������������������������������������������������������������������������������������������� 7 About Dartmouth-Hitchcock Health ����������������������������������������������������������� 8-11 About Geisel School of Medicine at Dartmouth 12-14 The Community ������������������������������������������������������������������������������������������������ 15 How To Apply ���������������������������������������������������������������������������������������������������� 16 Equal Opportunity Statement 16 2 The Opportunity Dartmouth-Hitchcock Health (D-HH) and the Geisel School of Medicine at Dartmouth have opened a search for a dynamic and engaging leader to provide strategic direction, oversight and collaborative leadership between the re- search functions at the Dartmouth-Hitchcock Medical Center and the Geisel School of Medicine at Dartmouth. Dartmouth-Hitchcock Health is an organization with significant depth in clinical and translational research. By pro- viding a centralized infrastructure to enhance patient safety, promote quality research, ensure fiscal and regulatory compliance, and encourage research collaboration, there exists a world-class opportunity that blends a highly attrac- tive environment with exceptional career opportunities. The Geisel School and Dartmouth-Hitchcock’s long-standing and deeply rooted commitments to research provide faculty, trainees and staff with state-of-the-art facilities as well as the important support they need at all stages of the research process. By linking other collaborators, facilitating studies and clinical trials, and helping navigate the ad- ministrative and regulatory landscape, our researchers have the foundation for research innovation and excellence. “ Our growing research infrastructure, in continuing collaboration with our colleagues at the Geisel School of Medicine at Dartmouth College, has Dartmouth-Hitchcock Health poised to join the ranks of the nation’s major academic health systems. From our NIH-funded Clinical and Translational Science Award program – SYNERGY - to our multidisciplinary research projects in all areas of medicine, Dartmouth-Hitchcock researchers are exploring innovative solutions to some of the major health issues facing our nation in more than 500 studies or trials that are actively enrolling across our system. We look forward to finding an experienced, forward-looking clinician- researcher to assume the new role of Chief Research Officer and lead us to the next level of research excellence.” ~ Joanne Conroy, MD President and CEO - Dartmouth-Hitchcock Health 3 Full Position Description Chief Research Officer, Dartmouth-Hitchcock Associate Dean of Clinical Research, Geisel School of Medicine at Dartmouth The Chief Research Officer/Associate Dean for Clinical Research will have the primary responsibilities of leading the strategic growth of the Dartmouth-Hitchcock (D-H) research portfolio and providing oversight of research-related operations and research compliance within D-H. In collaboration with the CTSA Director, the CRO will also foster productive collaborations among research programs within the broader Dartmouth community. The individual will serve as a member of the D-H and Geisel senior leadership teams and will be expected to make important contributions to the development and delivery of all key research strategies. Additionally, this role includes faculty/ teaching opportunities at the medical school. “The greatest challenges in human health will be overcome through the seamless integration of biomedical discovery and care delivery—the very space where Geisel excels. This would not be possible without our close clinical, research, and educational partnership with Dartmouth-Hitchcock.” ~ Duane Compton, PhD - Dean, Geisel School of Medicine at Dartmouth POSITION RESPONSIBILITIES: • Develop and implement a forward-looking strategic plan for growth of the research portfolio (clinical, translational, population-based) that will have impact locally, nationally and even internationally and that will promote a culture of innovation within D-H; • Develop strategies to promote the entrepreneurial efforts of faculty and the commercialization of D-H research including partnership with external partners; • Oversee the D-H research budget aligned to the strategic plan including financial commitments for faculty recruitment and retention, capital equipment, and research programs. Promote steps to facilitate long-term sustainability of the research programs; • Oversee the D-H Office of Research Operations and ensure that it provides outstanding service in the areas of grants management as well as compliance with all federal, state, and local requirements for clinical research programs; • Oversee the D-H Committee on the Protection of Human Subjects and ensure that all clinical research programs adhere to the highest ethical standards in collaboration with the D-H Research Compliance Officer and the D-H Office of General Counsel; • Serve as an Associate Director for Dartmouth’s Clinical and Translational Science Award (CTSA), SYNERGY, working with the SYNERGY Director to ensure that SYNERGY is optimally integrated into D-H’s larger research initiatives, and that D-H effectively participates in the national CTSA consortium; • Co-chair the Dartmouth Clinical and Translational Research Steering Committee; 4 Full Position Description (continued) • Serve as D-H’s principal research liaison to Dartmouth College (DC) leadership and create strategies to build effective synergies between D-H and DC-sponsored research programs; • Work closely with the Joint Development Office (JDO) to facilitate philanthropic/foundation support for D-H’s research goals/missions; • Oversee allocation of research space and equipment to programs and departments/centers; • Oversee training and communication to the members of the research community; • Review and in collaboration with appropriate partners, respond to all requests for waivers to institutional policies related to research program support and sponsorship; • Provide appropriate oversight of research training programs; • Provide ongoing evaluation of existing research programs; • Foster and facilitate proposal development and promote interaction for large multi-disciplinary research opportunities. REPORTING STRUCTURE: • Chief Clinical Officer, Dartmouth-Hitchcock Health • Dean – Geisel School of Medicine KEY RELATIONSHIPS: • D-H Chief Academic Officer/Dean, Geisel School of Medicine • Director, SYNERGY • Clinical Chairs & Center Directors, Dartmouth-Hitchcock • VP Office of Research Operations • D-H Senior Operations Team QUALIFICATIONS: • An MD, MD/PhD or other equivalent terminal degree and with academic credentials sufficient to meet eligibility for appointment at the rank of Associate Professor or (preferred) Professor • Outstanding scientific background with an established record of obtaining extramural funds • Demonstrated experience in leadership and management of research strategy and operations • Excellent interpersonal skills 5 About the Office of Research Operations The Office of Research Operations is the centralized administrative and operational “hub” across all Dartmouth- Hitchcock departments working to create mechanisms for connectedness between all research sites across D-HH. Through these important collaborations, we strive to enable the achievement of excellence across the research community. We achieve this by facilitating access to innovative and collaborative resources, applying those resources, and assisting with the coordination of services and activities. It is in this way that we are able to successfully catalyze interdisciplinary research across the translational pipeline. Specifically the Office of Research Operations is able to implement their operational expertise to: • Grants and Contracts • Research Space Allocation and Management • Research Capital Equipment Purchases • Technology Transfer • Research Communications • Research Budgeting and Contracts • Human Subjects Research Compliance 66 About SYNERGY Dartmouth SYNERGY: Clinical and Translational Science Institute The mission of SYNERGY, an NIH-funded CTSA Program, is to create a sustainable academic and physical home at Dartmouth (including the schools of Dartmouth College, Dartmouth-Hitchcock and the White River Junction VA) for the discipline of clinical and translational science. Our vision is to foster discovery, improve the infrastructure for clinical and translational science, nurture a cross-disciplinary collaborative spirit, enhance translational research training, and facilitate the development of innovative and efficient solutions for translating scientific discoveries into practice and improved population health. By creating an academic and physical home for the intellectual discipline of clinical and translational science, SYNERGY is transforming Dartmouth’s research and training environment. Specifically, SYNERGY: • Nurtures innovation by building connections and providing resources for discovery. • Addresses barriers to translational research. • Fosters collaborative interactions
Load more

Recommended publications
  • The Roles of Chief Research Officers at American Research Universities: a Current Profile and Challenges for the Future
    26 Droegemeier, Snyder, Knoedler, Taylor, Litwiller, Whitacre, Gobstein, Keller, Hinds, Dwyer The Roles of Chief Research Officers at American Research Universities: A Current Profile and Challenges for the Future Kelvin K. Droegemeier University of Oklahoma Lori Anderson Snyder University of Oklahoma Alicia Knoedler University of Oklahoma William Taylor University of Oklahoma Brett Litwiller University of Oklahoma Caroline Whitacre The Ohio State University Howard Gobstein Association of Public and Land-Grant Universities Christine Keller Association of Public and Land-Grant Universities Teri Lyn Hinds Association of Public and Land-Grant Universities Nathalie Dwyer Association of Public and Land-Grant Universities Abstract: The individual charged with stewarding the academic research and creative activity enterprise (i.e., Chief Research Officer or Vice President/Chancellor for Research), has tremendous responsibility and influence over the institution’s ability to achieve its overall mission. Yet, the skills and knowledge required to successfully serve in this role have not been comprehensively studied. To address this deficiency, we synthesize the views of 78 sitting Chief Research Officers to document the academic and experiential pathways of respondents, their current roles and responsibilities, and future challenges. We provide recommendations for effective ways of preparing future candidates for this important role. Keywords: Chief Research Officer; Vice President/Chancellor for Research; training; experience SOCIETY OF RESEARCH ADMINISTRATORS INTERNATIONAL Droegemeier, Snyder, Knoedler, Taylor, Litwiller, Whitacre, Gobstein, Keller, Hinds, Dwyer 27 A Current Profile and Challenges for the Future American research universities currently face an environment of change, marked by broad opportunities for growth in terms of research development, as well as many challenges (Brint, 2005).
    [Show full text]
  • CUPA Administrator 2017 Position Number Role Position Description Top Executive Officers
    CUPA Administrator 2017 Position Number Role Position Description Top Executive Officers: 100000 - 102000 100000 Chief Executive Officer, President. Directs all affairs and operations of a higher education system or System district. Each subordinate campus has its own President, Chancellor or Provost, administrative offices and independent programs. 101000 Chief Executive Officer, President or Chancellor. Directs all affairs and operations of a higher education Single Institution or Campus institution or of a campus within a system. within a System 102000 Executive Vice President/ Responsible for all or most functions and operations of an institution under the Vice Chancellor direction of the Chief Executive Officer. If the incumbent is also the Chief Academic Affairs Officer/Provost, report in 105000 and not here. Senior Institutional Officers: Positions 105000 - 145000 Persons in these positions direct a major functional area with institution-wide scope/impact and also the work of other professional employees. Reports to a top executive officer or to another senior institutional officer. 105000 Chief Academic Affairs Directs the academic program of the institution. Overall responsibilities typically Officer/ Provost include academic planning, teaching, research, extensions and coordination of interdepartmental affairs (e.g. Admissions, Registrar, and library activities). 107000 Chief Business Officer Responsible for the combined functions of administrative and financial affairs. Overall responsibilities typically include accounting, purchasing, physical plant and property management, human resources, food services, auxiliary enterprises, investments and related business matters. 109000 Chief Athletics Administrator Provides administrative direction and oversight for all intercollegiate, intramural and recreational athletics staff, programs, facilities and activities. Responsible for ensuring compliance with all federal, divisional and university athletics regulations and administering departmental funds and accounts.
    [Show full text]
  • MANAGEMENT INFORMATION CIRCULAR (Containing Information As at July 10, 2020 Unless Indicated Otherwise)
    MANAGEMENT INFORMATION CIRCULAR (Containing information as at July 10, 2020 unless indicated otherwise) PERSONS MAKING THE SOLICITATION This Management Information Circular (the “Information Circular”) is furnished in connection with the solicitation of proxies being made by the management (“Management”) of Poda Technologies Ltd. (the “Corporation”) for use at the Annual General and Special Meeting (the “Meeting”) of holders of common shares (the “Shareholders”) in the capital of the Corporation (the “Common Shares”) to be held on Monday, August 10, 2020 at 10:00 a.m. Pacific Daylight Savings Time at 10th Floor – 595 Howe Street, Vancouver, British Columbia, V6C 2T5 and for the purposes set forth in the accompanying Notice of Meeting. While it is expected that the solicitation will be made primarily by mail, proxies may be solicited personally or by telephone by Directors, officers and employees of the Corporation at nominal cost. All costs of this solicitation will be borne by the Corporation. The contents and the sending of this Information Circular have been approved by the Directors of the Corporation. Unless otherwise stated herein, all currency amounts indicated as “$” in this Information Circular are expressed in Canadian Dollars, the Corporation’s reporting currency. APPOINTMENT OF PROXYHOLDER AND VOTING BY PROXY The individuals named in the accompanying form of proxy are Directors or officers of the Corporation (the “Management Proxyholders”). A Shareholder wishing to appoint a person or company other than Management Proxyholders to attend and act for the Shareholder and on the Shareholder’s behalf at the Meeting has the right to do so, by striking out the names of the Management Proxyholders and by inserting the desired person’s or company’s name in the blank space provided in the proxy, or by executing a proxy in a form similar to the enclosed form.
    [Show full text]
  • March 2012 | Vol
    march 2012 | vol. 6, no.1 Research≤aryland@ connecting the university of maryland research community Gelfand Receives $3.6M Grant Supports START Research Humboldt International Research Prize A multidisciplinary center headquartered at the University A Maryland faculty researcher was of Maryland recently received a major federal grant to ex- recently recognized with a major pand its research on the human causes and consequences international award for her work in of terrorism. cross-cultural psychology. The science and technology directorate of the U.S. Department of Homeland Security (DHS) has Michelle Gelfand, awarded $3.6 million to the Center for the Study associate professor of Terrorism and Responses to Terrorism of psychology, has (START). The funding supports new research been named one of on social, behavioral and cultural factors that the first recipients influence terrorist behavior, violent extrem- of the Anneliese ism and counterterrorism efforts in the United Maier Research States and abroad. Award. She is one of only seven Since its 2005 launch, START has received international winners selected for almost $58 million in DHS funding. the prize from the Alexander von “They’ve been a proactive and productive center Humboldt Foundation. It includes of excellence that has served the Department of a monetary award of approxi- Homeland Security well,” says Matthew Clark, direc- mately $335,000, to be used for tor of the agency’s office of university programs. conducting cross-institutional With its mission to shape research and education research with colleagues and through the lens of public service, the science and scholar- specialists in Germany. ship at START parallels the university’s role as a modern land-grant institution, says Gary LaFree, START’s new projects include examining the emergence “I’m honored to receive this professor of criminology and the director and operations of domestic terrorists, as well as collecting award, which will stimulate deeper of START.
    [Show full text]
  • “Syndicated Third Party Research Is the Flashlight We
    ANA COMMERCIAL RATINGS SUMMIT Held January 22, 2013 @ Reed Smith, NYC Purpose The purpose of the Commercial Ratings Summit was to discuss solutions that could help facilitate the availability of brand-specific commercial ratings for television. The meeting was attended by ninety-two (92) individuals representing client-side marketers, agencies, media (network, cable, syndication), solution providers, industry trade associations, and other interested parties. ANA Member Historical Interest in Commercial Ratings ANA member interest in commercial ratings has remained consistently high over the years, per results from surveys done in 2004, 2006, and 2011. • 2004: How interested would you be in having TV commercial ratings readily and easily available? o Very Interested – 75%; Somewhat Interested – 21% (remainder either Ambivalent, Somewhat Disinterested or Very Disinterested) • 2006: How interested would you be in having TV commercial ratings readily and easily available? o Very Interested – 83%; Somewhat Interested – 13% (remainder either Ambivalent, Somewhat Disinterested or Very Disinterested) • 2011: Currently, ratings for individual commercials are not reported by Nielsen. Rather, Nielsen provides ratings for the average of all the commercials in a program (this is the metric called C3). How interested would you be in having ratings available for each individual commercial? o Interested – 82% (remainder either Neutral or Not Interested) Industry White Papers Supporting Commercial Ratings ANA has published two white papers in recent years advocating for commercial ratings: • March 2007: “Achieving Accountability: The Case for Brand-Specific Commercial Ratings.” • February 2010: “The Path to Brand-Specific Commercial Ratings.” In fact, this white paper was a joint collaboration with Nielsen. www.ana.net/commercialratings Even earlier, 4A’s published: • July 2001: “Commercial Ratings – Why We Need Them Now” 1 The Benefits of Commercial Ratings ANA members and other industry experts have identified numerous benefits for brand-specific commercial ratings.
    [Show full text]
  • 2015 New York Finance Forum
    2015 New York Finance Forum I. Introduction The New York Finance Forum brings together some of the most influential economists, financers, investors and entrepreneurs from U.S. and China, to initiate groundbreaking discussion on most recent development and trends of global economic and financial market. The forum provides those who participate an excellent platform to exchange the latest financial and investment news, expand professional network, and discover new partnerships and opportunities. While taking great effort to become one of the most influential financial platforms worldwide, the forum also seeks to establish a global financial think tank to provide strategic thinking and intellectual support to governments and financial institutes. Including the annual meeting, the forum plans to launch a series of online and offline theme events, and create a cooperative and mutually beneficial community for both U.S. and Chinese businessmen and scholars. The forum’s message will be sent out through new media, delivering enriched financial information with unique prospective. 1 II. About the Forum Co-Chairs: Hai Jin, Kaifeng Chen NYFF Preparatory Committee Members: Ming Cen, Jiyuan Chen, Kaifeng Chen, Kun Gao, Hai Jin, Haobo Lai, Xuhui Li, Ying Liu, Hongzhi Ma, Hengyong Mo, Zhiwen Wang, Chenyang Wei, Ke Zhang, Haixia Zhao, Jianqiang Zhu Sponsors: New York Finance Forum Preparatory Committee Columbia University School of Law China-U.S. Chamber of Commerce ICBC New York Northern Shipping Fund Marine Money International Sina Finance Association of FinTech And Big Data Professionals III. 2015 New York Finance Forum Theme and Agenda Theme: "Openness and Innovation: Financial Investment in the World under Reconstruction" Time: Sept.
    [Show full text]
  • Organization (As of July 1, 2020)
    Management system Organization (As of July 1, 2020) Corporate Strategic Planning Division Representative from Overseas General Administration & Communications Division President and Representative Board of Member of the Board, Legal & Compliance Division Directors Representative Member of the Board Human Resources Division Finance & Controller’s Division Executive Committee Quality Assurance Division Auditing Dept. Board of Intellectual Property Division Corporate Corporate Auditors Auditors Information Systems Division Purchasing & Logistics Division Corporate Auditors Office Corporate Marketing Planning Dept. Global Environment Business Strategic Planning Dept. Life Innovation Business Strategic Planning Dept. Branches Affiliated Companies Division Fibers & Textiles Division Resins & Chemicals Division Films Division Torayca & Advanced Composites Division Electronic & Information Materials Division Pharmaceuticals & Medical Products Division Water Treatment & Environment Division Technology Center Manufacturing Division Engineering Division Research & Development Division Toray Industries, Inc. Integrated Annual Report 2020 51 Members of the Board and Corporate Auditors (As of June 23, 2020) President and Representative Member of the Board Representative Member of the Board Akihiro Nikkaku Yukichi Deguchi Representative Member of the Board Mitsuo Ohya Representative Member of the Board Koichi Abe Member of the Board Masahiko Okamoto Member of the Board Satoru Hagiwara Member of the Board Minoru Yoshinaga Member of the Board Kazuyuki
    [Show full text]
  • Management Proxy Circular
    GABRIELLA'S KITCHEN INC. MANAGEMENT INFORMATION CIRCULAR NOTICE OF ANNUAL & SPECIAL MEETING OF SHAREHOLDERS JULY 30, 2019 2 NOTICE OF ANNUAL & SPECIAL MEETING OF SHAREHOLDERS OF GABRIELLA'S KITCHEN INC. NOTICE IS HEREBY GIVEN that the annual and special meeting of shareholders (the "Meeting") of Gabriella's Kitchen Inc. (the "Corporation" or "GABY") will be held on Thursday, August 29, 2019 at 11:00 a.m. (Calgary time) at the offices of Gowling WLG (Canada) LLP, located at Suite 1600, 421 - 7th Avenue S.W., Calgary, Alberta, T2P 4K9, for the following purposes: 1. to receive the consolidated annual financial statements of the Corporation, together with the auditor's report thereon, for the year ended December 31, 2018; 2. all shareholders will be asked to appoint Davidson & Company LLP, Chartered Professional Accountants, as auditor to hold office until the next annual meeting of shareholders at a remuneration to be fixed by the Board of Directors; 3. all shareholders will be asked to elect 6 directors of the Corporation to hold office until the next annual meeting of shareholders; 4. all shareholders will be asked to consider, and if thought fit, to pass a resolution to approve the adoption of the Corporation's stock option plan, as more particularly described in the accompanying management information circular; 5. all shareholders will be asked to consider, and if thought fit, to pass a special resolution to approve an amendment to the Corporation's Articles to change the name of the Corporation to "GABY Inc."; and 6. to transact such other business as may properly be brought before the meeting or any adjournments or postponements thereof.
    [Show full text]
  • Notice of AGM PDF 281KB
    Notice of AGM Notice of Annual General Meeting 2017 and Shareholders’ Circular Letter from the Chairman This document is important and requires your immediate attention If you are in any doubt about its contents or what action you should take, you should consult your Independent Financial Adviser. If you have sold or transferred all of your AstraZeneca ordinary shares you should send this document and the related documents to the purchaser or transferee or to the stockbroker, bank or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee. Dear Shareholder which is available on our website, Statement to AstraZeneca PLC on This letter is sent on behalf of the board of www.astrazeneca.com, or by request ceasing to hold office as UK statutory Directors (the Board) of AstraZeneca PLC from the Company. auditors pursuant to section 519 (the Company) and is to be read in > To confirm the first interim dividend of of the Companies Act 2006 conjunction with various documents US$0.90 (68.7 pence, SEK 7.81) per The circumstances connected with concerning your shareholding in the ordinary share and to confirm, as the final our ceasing to hold office as UK statutory Company. These documents are: dividend for 2016, the second interim auditors with effect from the end of dividend of US$1.90 (150.2 pence, the Annual General Meeting of 1 A Shareholders’ Circular incorporating SEK 16.57) per ordinary share. AstraZeneca PLC on 27 April 2017 are due to choosing to not participate the formal Notice of the Annual General in the audit tendering process.
    [Show full text]
  • Arbiton Inc. Stockholder Info and 10-K
    STOCKHOLDER INFORMATION ‰ APRIL 2013 Arbitron Executives Arbitron Board of Directors Sean R. Creamer Philip Guarascio President & Chief Executive Officer Chairman of Arbitron Inc.; Chairman and Chief Executive Officer, PG Ventures LLC; formerly Vice Debra Delman President and General Manager, General Motors Executive Vice President, Corporation in charge of North America Advertising Finance and Chief Financial Officer and Corporate Marketing Manish Bhatia Shellye Archambeau Executive Vice President, Chief Executive Officer, MetricStream, Inc. New Product Innovation Sean R. Creamer Carol Hanley President & Chief Executive Officer, Arbitron Inc. Executive Vice President, Chief Sales & Marketing Officer David W. Devonshire Formerly Executive Vice President and Chief Financial V. Scott Henry Officer, Motorola, Inc. Executive Vice President, Technology Solutions John Dimling Marilou Legge Advisor, C3 Metrics; Formerly Chairman, President, Executive Vice President, Organization Effectiveness & and Chief Executive Officer, Nielsen Media Corporate Communications Research, Inc.; Inductee, Market Research Council’s Hall of Fame Gregg Lindner Executive Vice President, Erica Farber Service Innovation and Chief Research Officer President and Chief Executive Officer, Radio Advertis- ing Bureau; formerly CEO of The Farber Connection Steven M. Smith LLC; formerly Publisher/President of Radio & Records Executive Vice President, Survey Operations Ronald G. Garriques Timothy T. Smith Chief Executive Officer and Chairman of Gee Holdings Executive Vice President,
    [Show full text]
  • Emerging Managers & Diversity
    TALKING HEDGE Emerging Managers & Diversity: What No One is Talking About—Yet March 30, 2017 | The Conference Center, UBS Tower CONFERENCE GUIDE CONFERENCE SPONSORS TALKING HEDGE Welcome to the delegation of Emerging Managers & Diversity: What No One is Talking About—Yet. We are delighted you can join us and confident that you will receive a solid return on your investment in this event. Our sincere appreciation to all of our sponsors for recognizing the value of this forum and collaborating with us to ensure its success. We formed Talking Hedge to bring together the best minds in alternative investing—allocators, managers and solutions providers—to have open and candid discussions about the challenges each group faces. Our events are designed specifically to give you time to talk and time to meet in a meaningful way. Our goal is for you to walk away with the information you need to meet the challenges of tomorrow. We would also like to thank our stellar speaking faculty for taking the time to develop thoughtful and thought-provoking sessions that will provide much to discuss over coffee and cocktails. We look forward to a constructive day of conversation and networking! Kind regards, Kristin Fox Meg Bode Co-founder Co-founder CONFERENCE PROGRAM MARCH 30, 2017 8:00-8:30 Breakfast & Registration 8:30-9:45 Investor/Manager Sessions Investor Peer-to-Peer Moderated Networking Facilitator: Terri Engleman Rhoads President & Managing Partner, Kettera Strategies Manager Workshop: Achieving Perfect Pitch: An interactive workshop designed to help
    [Show full text]
  • About Rentrak
    About Rentrak For more than two decades, entertainment insiders have relied on Rentrak’s innovative software and progressive technology to interpret their complex audience data and drive their businesses and the industry forward. Entertainment providers from across the industry utilize Rentrak’s revolutionary products and services to gain the insights needed to better understand their audiences and effectively compete in an increasingly complex environment. Our experience transforming unprecedented amounts of data – including hundreds of billions of set-top box transactions – combined with our incomparable customer service and support, has solidified Rentrak’s position in the center of the media and entertainment marketplace. Today, Rentrak is a global company with offices in fifteen cities and eleven countries. The media and entertainment advertising sectors continue to evolve, and Rentrak is prepared and committed to navigate each step of the way – from data to information to knowledge. We invite you to visit us online at Rentrak.com to learn more. LetteR to SharehoLders ...............................................................................................................A 2 Board of diRectors & coRporate executiveS ............................................................................A 6 finAncial Summary .........................................................................................................................A 8 foRm 10-K ...........................................................................................................................................1
    [Show full text]